EUVIMEDEUVIMED entdecken
Kohortenstudie

A retrospective cohort study of coagulation function in patients with liver cirrhosis receiving cefoperazone/sulbactam with and without vitamin K1 supplementation

Jianmo Liu, Jingyang Xiao, HongFei Wu, Jinhua Ye, Yun Li, Bin Zou, Yixiu Li

International Journal of Clinical Pharmacy · 2024

DOI: 10.1007/s11096-024-01796-w ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift International Journal of Clinical Pharmacy, 2024. Verfasst von Jianmo Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Science and Technology, The Second Affiliated Hospital of Nanchang University, Nanchang, 330006, Jiangxi, China. Hauptthemen laut MEDLINE: Liver Cirrhosis, Sulbactam, Cefoperazone, Blood Coagulation. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 21 Literaturangaben. Gefördert von: Natural Science Foundation of Jiangxi Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Cefoperazone/sulbactam is commonly prescribed for the treatment of infected patients with cirrhosis. AIM: To investigate the effect of cefoperazone/sulbactam on coagulation in cirrhotic patients and assess the effectiveness of vitamin K1 supplementation in preventing cefoperazone/sulbactam-induced coagulation disorders. METHOD: This retrospective cohort study compared coagulation function in 217 cirrhotic patients who received cefoperazone/sulbactam with and without vitamin K1 supplementation (vitamin K1 group, n = 108; non-vitamin K1 group, n = 109). Propensity score matching (PSM) was used to to reduce confounders' influence, the SHapley additive exPlanations (SHAP) model to explore the importance of each variable in coagulation disorders. RESULTS: In the non-vitamin K1 group, the post-treatment prothrombin time (PT) was 16.5 ± 6.5 s and the activated partial thromboplastin time (aPTT) was 34.8 ± 9.4 s. These were significantly higher than pre-treatment values (PT: 14.6 ± 2.4 s, p = 0.005; aPTT: 30.4 ± 5.9 s, p < 0.001). In the vitamin K1 group, no differences were observed in PT, thrombin time, or platelet count, except for a slightly elevated post-treatment aPTT (37.0 ± 10.4 s) compared to that of pre-treatment (34.4 ± 7.2 s, p = 0.033). The vitamin K1 group exhibited a lower risk of PT prolongation (OR: 0.211, 95% CI: 0.047-0.678) and coagulation disorders (OR: 0.257, 95% CI: 0.126-0.499) compared to that of the non-vitamin K1 group. Propensity score matching analysis confirmed a reduced risk in the vitamin K1 group for prolonged PT (OR: 0.128, 95% CI: 0.007-0.754) and coagulation disorders (OR: 0.222, 95% CI: 0.076-0.575). Additionally, the vitamin K1 group exhibited lower incidences of PT prolongation, aPTT prolongation, bleeding, and coagulation dysfunction compared to the non-vitamin K1 group. CONCLUSION: Cefoperazone/sulbactam use may be linked to a higher risk of PT prolongation and coagulation disorders in cirrhotic patients. Prophylactic use of vitamin K1 can effectively reduce the risk.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver CirrhosisSulbactamCefoperazoneBlood CoagulationAnti-Bacterial AgentsBlood Coagulation DisordersVitamin K 1HumansRetrospective StudiesMaleFemaleMiddle AgedAgedCohort StudiesDietary SupplementsPartial Thromboplastin TimeAdult

Stichwörter der Autor:innen

Cefoperazone/sulbactamCoagulation disorderLiver cirrhosisVitamin K1

Substanzen

SulbactamCefoperazoneAnti-Bacterial AgentsVitamin K 1

Autor:innen und Institutionen

  • Department of Science and Technology, The Second Affiliated Hospital of Nanchang University, Nanchang, 330006, Jiangxi, China.
  • Department of Pharmacy, The Second Affiliated Hospital of Nanchang University, Nanchang, 330006, Jiangxi, China.
  • Jiangzhong Pharmaceutical Co., Ltd., Nanchang, 330049, Jiangxi, China.
  • Department of Pharmacy, The Second Affiliated Hospital of Nanchang University, Nanchang, 330006, Jiangxi, China. 396112445@qq.com.

Förderung

  • Natural Science Foundation of Jiangxi Province

Zitieren

APA

Liu, J., Xiao, J., Wu, H., Ye, J., Li, Y., Zou, B., & Li, Y. (2024). A retrospective cohort study of coagulation function in patients with liver cirrhosis receiving cefoperazone/sulbactam with and without vitamin K1 supplementation. International Journal of Clinical Pharmacy. https://doi.org/10.1007/s11096-024-01796-w

Vancouver

Liu J, Xiao J, Wu H, Ye J, Li Y, Zou B, et al. A retrospective cohort study of coagulation function in patients with liver cirrhosis receiving cefoperazone/sulbactam with and without vitamin K1 supplementation. International Journal of Clinical Pharmacy. 2024. doi:10.1007/s11096-024-01796-w

BibTeX
@article{Liu2024,
  author = {Liu, Jianmo and Xiao, Jingyang and Wu, HongFei and Ye, Jinhua and Li, Yun and Zou, Bin and Li, Yixiu},
  title = {A retrospective cohort study of coagulation function in patients with liver cirrhosis receiving cefoperazone/sulbactam with and without vitamin K1 supplementation},
  journal = {International Journal of Clinical Pharmacy},
  year = {2024},
  doi = {10.1007/s11096-024-01796-w}
}
Kostenlos starten →